MA28810B1 - Modulateurs de kinases a base de pyrrolopyridine - Google Patents

Modulateurs de kinases a base de pyrrolopyridine

Info

Publication number
MA28810B1
MA28810B1 MA29695A MA29695A MA28810B1 MA 28810 B1 MA28810 B1 MA 28810B1 MA 29695 A MA29695 A MA 29695A MA 29695 A MA29695 A MA 29695A MA 28810 B1 MA28810 B1 MA 28810B1
Authority
MA
Morocco
Prior art keywords
pyrrolopyridine
modulators
kinases
based kinases
tptskagsgapggtskgpaeesrvrrhkhssespgrdkgklsrlkpapp
Prior art date
Application number
MA29695A
Other languages
English (en)
Inventor
William D Arnold
Pierre Bounaud
Andreas Gosberg
Zhe Li
Ian Mcdonald
Ruo W Steensma
Mark E Wilson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of MA28810B1 publication Critical patent/MA28810B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNS 1 50 KENLLAGPSEMDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWC 51 100 EAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFL 101 150 VRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVH 151 200 HHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGG 201 250 GQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQ 251 300 LLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSA 301 350 MEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAK 351 400 FPIKWTAPESLAYNKFSKSIDVWAFGVLLWEIATYGMSPYPGIDLSQVYE 401 450 LLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQES 451 500 SISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEM 501 550 PHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLF 551 600 SALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTP 601 650 LDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLAT 651 700 GEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSS 701 750 TFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKD 751 800 IMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAEKGSALGTPAAAEP 801 850 VTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPP 851 900 PPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQ 901 950 PGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSST 951 1000 AFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQM 1001 1050 ASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQIC 1051 1100 PATAGSGPAATQDFSKLLSSVKEISDIVQR 1101 1130
MA29695A 2004-07-27 2007-02-21 Modulateurs de kinases a base de pyrrolopyridine MA28810B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59188704P 2004-07-27 2004-07-27
US59188804P 2004-07-27 2004-07-27
US68351005P 2005-05-19 2005-05-19

Publications (1)

Publication Number Publication Date
MA28810B1 true MA28810B1 (fr) 2007-08-01

Family

ID=35262080

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29695A MA28810B1 (fr) 2004-07-27 2007-02-21 Modulateurs de kinases a base de pyrrolopyridine

Country Status (15)

Country Link
US (3) US7361763B2 (fr)
EP (2) EP1781654A1 (fr)
JP (1) JP2008508303A (fr)
KR (1) KR20070053237A (fr)
AU (1) AU2005269386A1 (fr)
BR (1) BRPI0513916A (fr)
CA (1) CA2573362A1 (fr)
EC (1) ECSP077280A (fr)
IL (1) IL180790A0 (fr)
MA (1) MA28810B1 (fr)
MX (1) MX2007001127A (fr)
NO (1) NO20070907L (fr)
NZ (1) NZ553267A (fr)
TN (1) TNSN07027A1 (fr)
WO (1) WO2006015123A1 (fr)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
CA2550361C (fr) 2003-12-19 2014-04-29 Prabha Ibrahim Composes et methodes de developpement de modulateurs de ret
TWI372624B (en) * 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1781654A1 (fr) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Modulateurs de kinases à base de pyrrolopyridine
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
EP1828180A4 (fr) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1h -pyrrolo[2,3-beta]pyridines
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
KR101411167B1 (ko) 2005-04-13 2014-06-23 아스텍스 테라퓨틱스 리미티드 하이드록시벤즈아미드 유도체 및 ｈｓｐ90 억제제로서의이의 용도
AU2006272951A1 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN102532133A (zh) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
MX2008014450A (es) * 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2073802A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP2010508363A (ja) * 2006-11-01 2010-03-18 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
WO2008060907A2 (fr) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Nouveaux inhibiteurs de la kinase
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
WO2008063888A2 (fr) * 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
AU2007336811A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
AU2008210455A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
GB0702259D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
GB0702265D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-Azaindole derivatives
WO2008124848A1 (fr) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Modulateurs hétérocycliques à cycles fusionnés pour les kinases
US8263585B2 (en) * 2007-05-04 2012-09-11 Novartis Ag Organic compounds
CA2688823A1 (fr) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Modulateurs heterocycliques des kinases
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
EP2176216B1 (fr) * 2007-07-06 2012-04-25 Paratek Pharmaceuticals, Inc. Procédés servant à synthétiser de minocycline 9-substituée
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
ES2394126T3 (es) * 2007-07-26 2013-01-22 Novartis Ag Derivados de pirimidina útiles para el tratamiento de estados inflamatorios o alérgicos
US8183245B2 (en) * 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
US8598165B2 (en) 2007-11-26 2013-12-03 University Of Kansas Morpholines as selective inhibitors of cytochrome P450 2A13
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2009143211A2 (fr) 2008-05-21 2009-11-26 Incyte Corporation Sels de 2-fluoro-n-méthyl-4-[7-(quinoléin-6-yl-méthyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide et procédés associés à leur préparation
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
ES2402087T3 (es) 2008-07-23 2013-04-26 Vertex Pharmaceuticals Incorporated Inhibidores de la pirazolopiridina quinasa
NZ590688A (en) 2008-08-05 2012-09-28 Daiichi Sankyo Co Ltd imidazo[4,5-b]pyridin-2-one derivatives
EP2323659A4 (fr) * 2008-08-05 2012-03-14 Abbott Lab Composés utiles comme inhibiteurs de protéine kinases
MX2011001319A (es) * 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
CA2744498C (fr) 2008-11-25 2017-10-24 University Of Rochester Inhibiteurs de mlk et procedes d'utilisation
CA3121743A1 (fr) * 2009-01-15 2010-07-22 Incyte Holdings Corporation Procedes de preparation d'inhibiteurs de jak et composes intermediaires apparentes
FR2941948B1 (fr) 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
CA2760705A1 (fr) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2266562A1 (fr) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Utilisation de dérivés des indoles pour le traitement du cancer
US8329724B2 (en) * 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
GB0918924D0 (en) * 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP3795573B1 (fr) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certaines triazolopyrazines, leurs compositions et leurs procédés d'utilisation
WO2011094288A1 (fr) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyrazine kinase
EP2528917B1 (fr) 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Pyrazolopyridines utiles dans le traitement de maladies auto-immunes, inflammatoires ou (hyper)proliferatives
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
CA2795422A1 (fr) * 2010-04-19 2011-10-27 Abbvie Inc. Inhibiteurs pyrrolopyridine de kinases
AU2011248175A1 (en) * 2010-05-06 2012-10-25 Merck Sharp & Dohme Corp. Aza-Indole derivatives useful as modulators of FAAH
AU2011258465B2 (en) 2010-05-24 2016-12-15 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US8779150B2 (en) * 2010-07-21 2014-07-15 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012135631A1 (fr) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc 5-(pyrazin-2-yl)-1h-pyrazolo[3,4-b]pyridine substituée et dérivés de pyrazolo[3,4-b]pyridine en tant qu'inhibiteurs de protéine kinase
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2763535B1 (fr) * 2011-10-03 2017-06-07 Merck Sharp & Dohme Corp. Azaindoles en tant qu'inhibiteurs de janus kinase
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2925319B1 (fr) 2012-11-30 2019-01-09 University Of Rochester Inhibiteurs de kinase de lignage mixte pour des thérapies pour le vih/sida
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN104119331B (zh) * 2013-04-26 2018-02-06 广东东阳光药业有限公司 烯基化合物及其使用方法和用途
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
CA2973597A1 (fr) * 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Inhibiteurs d'itk heterocycliques pour traiter l'inflammation et le cancer
KR101660863B1 (ko) * 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
US10160755B2 (en) * 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2017094026A1 (fr) * 2015-11-30 2017-06-08 Council Of Scientific & Industrial Research Pyridines 3-pyrimidinyl pyrrolo [2,3-b] utilisées comme nouveaux agents anticancéreux et leur procédé de préparation
RU2018123825A (ru) * 2015-12-07 2020-01-15 Плексксикон Инк. Соединения и способы для модуляции киназ, и показания для этого
WO2018217766A1 (fr) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Composés d'amélioration de l'expression de kcc2 et leurs utilisations
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
CN107550905B (zh) * 2017-09-11 2020-07-17 浙江永宁药业股份有限公司 多取代吡咯并吡啶类化合物的药物用途及其制备方法
WO2019057660A1 (fr) * 2017-09-25 2019-03-28 Basf Se Composés d'indole et d'azaindole ayant des cycles aryle et hétéroaryle à 6 chaînons substitués en tant que fongicides agrochimiques
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
WO2019169306A1 (fr) * 2018-03-01 2019-09-06 The Trustees Of Columbia University In The City Of New York Composés, compositions et procédés pour supprimer un stress toxique du réticulum endoplasmique
TW202039483A (zh) * 2018-11-22 2020-11-01 英屬開曼群島商百濟神州有限公司 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途
KR20220018475A (ko) * 2019-04-09 2022-02-15 플렉시콘 인코퍼레이티드 Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
TW202116771A (zh) 2019-07-17 2021-05-01 英屬開曼群島商百濟神州有限公司 作為ｈｐｋ１抑制劑之三環化合物及其用途
JP7564888B2 (ja) * 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
EP4225741A4 (fr) * 2020-10-05 2024-10-30 Enliven Inc. Composés de 7-azaindole pour l'inhibition de tyrosine kinases bcr-abl
WO2022243648A1 (fr) * 2021-05-21 2022-11-24 Centre National De La Recherche Scientifique (Cnrs) Nouveaux derives azaindole en tant qu'agents antiviraux
WO2023245327A1 (fr) * 2022-06-20 2023-12-28 Biofront Ltd Agents de dégradation de kinases multiples, compositions comprenant l'agent de dégradation et leurs procédés d'utilisation
WO2023245329A1 (fr) * 2022-06-20 2023-12-28 Biofront Ltd Inhibiteurs de kinases multiples, compositions de ceux-ci et leurs procédés d'utilisation

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
US5019586A (en) 1987-04-14 1991-05-28 Glaxo Group Limited Ketone derivatives
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP2886748B2 (ja) * 1992-09-17 1999-04-26 富士写真フイルム株式会社 写真用処理組成物及び処理方法
GB9416162D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
AU5645196A (en) 1995-04-11 1996-10-30 Lonza A.G. Process for preparing azaindoles with an activated copper ch romite catalyst by catalytic dehydrocyclisation of alkylpyri dylamines (pyridopyridines)
WO2000024694A1 (fr) 1998-10-28 2000-05-04 Eli Lilly And Company Procede photochimique pour l'obtention de derives 1-desoxy-2-ceto
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
DE19955915C2 (de) 1999-11-20 2001-09-13 Wella Ag Tryptophanderivate und Tryptophanase enthaltende Haarfärbemittel sowie Verfahren zur enzymatischen Haarfärbung
DE10053122A1 (de) 1999-11-20 2001-05-23 Wella Ag Verfahren zur Herstellung von Indolen sowie die Verwendung dieser Indole in Färbemitteln
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
AU2001287898A1 (en) 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
MXPA03005432A (es) 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilindazol y -azaindazol como ligandos de 5-hidroxitriptamina-6.
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003028724A1 (fr) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de la kinase chk1
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
IL164082A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd Azaindole derivatives and pharmaceutical compositions containing the same
EP1490364B1 (fr) * 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n pour le traitement de troubles neurodegeneratifs
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
EP1545515A1 (fr) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
AU2003272548A1 (en) 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
EP1560582A4 (fr) 2002-10-09 2008-03-12 Scios Inc DERIVES D'AZAINDOLE UTILISES EN TANT QU'INHIBITEURS DE LA KINASE p38
JP4787150B2 (ja) * 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｊｎｋ阻害剤
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004101565A2 (fr) * 2003-05-16 2004-11-25 Eisai Co., Ltd. Inhibiteurs des jnk
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
CA2550361C (fr) * 2003-12-19 2014-04-29 Prabha Ibrahim Composes et methodes de developpement de modulateurs de ret
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
FR2865313B1 (fr) 2004-01-15 2006-06-09 Diamecans Dispositif de manoeuvre bistable d'arbre mobile non traversant et coupe-circuit de batterie comprenant un tel dispositif
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
TWI372624B (en) * 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
EP1781654A1 (fr) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Modulateurs de kinases à base de pyrrolopyridine
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
DE602006014540D1 (en) 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren

Also Published As

Publication number Publication date
IL180790A0 (en) 2007-06-03
NO20070907L (no) 2007-04-16
US20090306056A1 (en) 2009-12-10
WO2006015123A1 (fr) 2006-02-09
JP2008508303A (ja) 2008-03-21
CA2573362A1 (fr) 2006-02-09
EP1781654A1 (fr) 2007-05-09
US7582637B2 (en) 2009-09-01
BRPI0513916A (pt) 2008-05-20
US20060030583A1 (en) 2006-02-09
MX2007001127A (es) 2007-07-11
US20080221119A1 (en) 2008-09-11
ECSP077280A (es) 2007-03-29
NZ553267A (en) 2010-09-30
US7906648B2 (en) 2011-03-15
EP2264033A1 (fr) 2010-12-22
AU2005269386A1 (en) 2006-02-09
TNSN07027A1 (en) 2008-06-02
US7361763B2 (en) 2008-04-22
KR20070053237A (ko) 2007-05-23

Similar Documents

Publication Publication Date Title
MA28810B1 (fr) Modulateurs de kinases a base de pyrrolopyridine
NO20044597L (no) Kjemiske forbindelser
IN2014CN03629A (fr)
SG145694A1 (en) Novel compounds
SG147409A1 (en) Amide derivatives
IN2014CN03762A (fr)
AU150501S (en) A toothbrush
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
FI20022024A0 (fi) Synkronointi-istunnon järjestäminen
DK1492789T3 (da) Tropanderivater som CCR5-modulatorer
DK1761497T3 (da) Azadecalinglucocorticoidreceptormodulatorer
ATE456558T1 (de) Gabanerge modulatoren
NO20044448L (no) Nye forbindelser
NO20035183D0 (no) 5-substituerte-2-arylpyridiner som CRF1 modulatorer
EA200700766A1 (ru) Способ получения производных [1,4,5]-оксадиазепина
ATA10122001A (de) Höhenverstellbare trägerplatte
UA51375A (uk) Канатно-скреперна установка
DOP2002000329A (es) Composicion solida
UA50920A (uk) Опорно-центруючий пристрій
DE50300775D1 (de) Zweipunkt-modulatoranordnung
MD2731B2 (fr)
ES1052229Y (es) Base de andamio.
FI20041274L (fi) Aluskilpi
AU2003204288B2 (en) Base of LED
ES1054258Y (es) Base de enchufe